"Pre-treating pain associated with venous access procedures is the right thing to do, and parents should feel comfortable asking how pain can be minimized for their child," said Micke A. Brown, BSN, RN, director of advocacy, American Pain Foundation. "Regular use of topical anesthetics to lessen a painful needlestick can be a nurse's best friend. It allows us to quickly gain patient trust and sets a therapeutic tone that positively affects the hospital experience."
Anesiva will provide updated information on the commercialization plan for Zingo in the coming weeks. In addition, Anesiva is now studying Zingo in a large Phase 3 trial in adults. The company will use the data generated in that trial as the basis for an FDA filing to expand the label to include adults.
There may be opportunities to use the needle-free delivery technology employed in Zingo for the delivery of drugs other than lidocaine. Possible drug candidates include insulin, human growth hormone, erythropoietin, calcitonin, and other medications, excluding vaccines. The company may license the rights to the use of this technology for such other medications to third parties.
Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories.'/>"/>
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.